As our recent studies found ASC‐J9®, a small molecule that could enhance AR degradation,47, 48, 49, 50, 51, 52 could also function through AR‐independent pathways to suppress prostate cancer metastasis via inhibiting p‐STAT3 expression (14), we therefore combined Sorafenib with ASC‐J9® to examine their potential efficacy to suppress HCC. Here, STAT3 is linked to prostate carcinoma.